These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2008-001804-22||A Phase III, randomized, parallel group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus placebo for pre-operative treatment of sy...||bad-data|
|Listed as ongoing, but also has a completion date||2008-001805-40||A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (le...||2010-08-27||bad-data|
|Not reported||2010-018999-25||A Phase III, multicentre, clinical study investigating the efficacy and safety of 3-months open-label treatment with PGL4001, followed by a randomised, double-blind placebo controlled period of 10 day...||2012-02-02||due-trials|
|Listed as ongoing, but also has a completion date||2010-019497-32||A Phase III, multicentre, clinical study investigating the efficacy and safety of three successive periods of 3-month open-label PGL4001 treatment, each followed by ten days of double-blind treatment ...||2013-02-27||bad-data|
|Listed as ongoing, but also has a completion date||2011-005167-24||A Phase II, Multicentre, Randomised, Two-Arm, Parallel Group, Double-Blind, Placebo controlled Study of the Steroid Sulfatase Inhibitor PGL2001 with concomitant administration of NETA (norethisterone ...||2014-02-28||bad-data|
|Not reported||2012-000036-26||A Phase III, multicentre, randomized, double-blind clinical study, investigating the efficacy and safety of repeated 12-week courses of daily 5mg or 10mg doses of PGL4001 for the long-term management ...||2015-01-19||due-trials|
|Not reported||2012-001219-22||A Phase IIa study investigating the efficacy and safety of the c-Jun-N-Terminal Kinase (JNK) inhibitor PGL5001 versus placebo administered for up to 5 months with concomitant administration of depot m...||2014-05-06||due-trials|
|Listed as ongoing, but also has a completion date||2012-001465-33||A Phase III, multicentre, extension study investigating the||2015-04-19||bad-data|